# Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy

> **NCT00674323** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 61 (actual)

## Conditions studied

- Polypoidal Choroidal Vasculopathy

## Interventions

- **DRUG:** Verteporfin Photodynamic Therapy
- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT00674323
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2009-05
- **Final completion:** —
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2011-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00674323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00674323, "Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00674323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*